3Fontenot JD, Rasmussen JP, GavinMA, et al. A function for in- terleukin 2 in Foxp3-expressing regulatory T cells [J]. Nat im- munol, 2005 Nov, 6 (11): 1142 - 1151.
4Johnson RW, Dworkin RH. Treatment of herpes zoster and posther- petic neuralgia [J]. BMJ, 2003, 326 (7392): 748-750.
6Stankus SJ, Dlugopolski M, Packer D. Management of her pes zoster (shingles) and postherpetic neuralgia [J]. Am Faro Physi- cian, 2000, 61 (8): 2437-2444, 2447-2448.
7Whitley R J, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster [J]. J Infect Dis, 1998, 178 (Suppl 1): S71-S75.
8Cunningham AL, Dworkin RH. The management of post-herpeticneuralgia [J]. BMJ, 2000, 321 (7264): 778-779.
9Kotani N, Kudo R, Sakurai Y. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neu- ralgia [J]. AmJMed, 2004, 116 (5): 318-324.
